Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MGA271 · 1 trial · 7 indications
Adverse events, serious adverse events, ECG monitoring, adrenal function monitoring, monitoring for development of anti-drug antibodies
| Arm | Type | Description |
|---|---|---|
| MGA271 | EXPERIMENTAL | Fc-optimized, humanized monoclonal antibody |
| Name | Type | Description |
|---|---|---|
| MGA271 | BIOLOGICAL | Up to 9 dose escalation cohorts will be enrolled to determine the maximum tolerated dose of MGA271. Patients with evidence of clinical benefit will be allowed to continue therapy at the same dose once per week for 3 weeks out of every 4-week cycle until documented progression. Patients treated in the Expansion Segment at the maximum administered dose will receive weekly, uninterrupted infusions of MGA271 in 8 week cycles for up to 12 cycles. |
Inclusion Criteria: * Histologically or cytologically confirmed carcinoma (prostate cancer, renal cell carcinoma, head and neck cancer, triple-negative breast cancer, bladder cancer, non-small cell lung cancer) or melanoma that overexpresses B7-H3. * Progressive disease during or after last treatme...
Top 20 of 53 competitors
MGA271 is an investigational monoclonal antibody being studied for the treatment of prostate cancer. It is also being evaluated in other refractory cancers, including melanoma, renal cell carcinoma, triple-negative breast cancer, head and neck cancer, bladder cancer, and non-small cell lung cancer.
MGA271 is being developed by MacroGenics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol MGNX. The company is conducting clinical research to evaluate the safety and efficacy of this investigational therapy.
MGA271 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The Phase 1 trial has been completed, and the drug remains under clinical investigation for the treatment of prostate cancer and other refractory cancers.
MGA271 has been studied in one clinical trial, identified as NCT01391143, titled 'Safety Study of MGA271 in Refractory Cancer.' This Phase 1 trial enrolled 179 participants and has been completed. The trial was conducted in the United States and included patients with prostate cancer and other advanced solid tumors.
MGA271 is a monoclonal antibody, a type of targeted therapy designed to bind to specific proteins on cancer cells. As a monoclonal antibody, it is intended to interfere with cancer cell growth or survival, although the specific molecular target of MGA271 has not been disclosed in the available information.